Sumitomo Dainippon Pharma Co., Ltd. / Otsuka Pharmaceutical Co., Ltd.

Schizophrenia and adjacent CNS disorders (TAAR1 and 5-HT1A pathway)

2.6M US cases/yr · $10.0B Global schizophrenia drug sales 2021 (USD MM) · 30 Percent treatment-resistant schizophrenia (%)

Disease Overview

Schizophrenia is a chronic, severe psychiatric disorder affecting roughly 2.6 million US adults (~0.85-1.0% lifetime prevalence per NIMH and the 2022 GBD study), with onset typically in late adolescence to early adulthood. Standard-of-care antipsychotics (D2/5-HT2A receptor antagonists/partial agonists) including olanzapine, risperidone, aripiprazole, paliperidone, lurasidone, brexpiprazole and cariprazine produce meaningful improvement in positive symptoms but leave large unmet needs in negative symptoms (anhedonia, avolition, social withdrawal), cognitive dysfunction, and metabolic/extrapyramidal side effects that drive ~40-60% non-adherence and 5x higher all-cause mortality versus the general population. Approximately 20-30% of patients have treatment-resistant disease and require clozapine, the only agent with proven efficacy in this subset but encumbered by mandatory ANC monitoring. Global schizophrenia drug sales were ~$10 billion in 2021 and are projected to grow modestly with long-acting injectables (Invega Sustenna/Trinza/Hafyera, Aristada, Rykindo) and novel mechanisms. The 2024 FDA approval of Cobenfy (xanomeline-trospium, Bristol Myers Squibb via Karuna acquisition) — the first non-D2 antipsychotic in 70 years — transformed the competitive landscape.

Competitive Landscape

At deal date, ulotaront (SEP-363856) was the most advanced TAAR1/5-HT1A agonist in development, having received FDA Breakthrough Therapy designation in May 2019 on the back of a positive Phase 2 schizophrenia readout published in NEJM 2020 (Koblan et al.). Sunovion's Phase 3 DIAMOND program (DIAMOND 1 + DIAMOND 2 acute schizophrenia trials, plus open-label extension) was running in 2021. Competitive landscape for non-D2 mechanisms in schizophrenia: Karuna Therapeutics' KarXT (xanomeline-trospium, M1/M4 muscarinic agonist + peripheral antagonist) was in Phase 3 EMERGENT-2/3 — subsequently acquired by BMS for $14B in Dec 2023 and approved as Cobenfy Sep 2024. Other Phase 2/3 mechanisms: Cerevel Therapeutics emraclidine (selective M4 PAM, Phase 2 data Sep 2021, acquired by AbbVie Aug 2024 for $8.7B), Roche pimavanserin (5-HT2A inverse agonist, failed Phase 3 ENHANCE adjunctive 2019), Minerva Neurosciences roluperidone (5-HT2A/sigma-2, CRL Feb 2024). The other three Sumitomo/Otsuka collaboration assets included SEP-378614 (D2/5-HT1A partial agonist), SEP-380135 (alpha-adrenergic) and a fourth undisclosed CNS asset. Ulotaront’s Phase 3 DIAMOND 1 and DIAMOND 2 readouts in July 2023 missed primary endpoints, leading to discontinuation of the schizophrenia indication.